$512 Million is the total value of VR Adviser, LLC's 25 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 39.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VRDN | VIRIDIAN THERAPEUTICS INC | $68,684,566 | -12.9% | 2,699,865 | 0.0% | 13.41% | +0.9% | |
| COGT | Buy | COGENT BIOSCIENCES INC | $52,708,902 | +12.9% | 4,884,977 | +21.0% | 10.29% | +30.9% |
| New | ENLIVEN THERAPEUTICS INC | $48,489,710 | – | 2,214,142 | +100.0% | 9.47% | – | |
| TERN | Sell | TERNS PHARMACEUTICALS INC | $42,855,140 | +13.5% | 3,619,522 | -2.4% | 8.37% | +31.6% |
| PLRX | Buy | PLIANT THERAPEUTICS INC | $38,038,000 | +82.2% | 1,430,000 | +32.4% | 7.43% | +111.2% |
| AMAM | New | AMBRX BIOPHARMA INCsponsored ads | $29,423,307 | – | 3,298,577 | +100.0% | 5.74% | – |
| GHRS | GH RESEARCH PLCordinary shares | $28,101,829 | -17.8% | 3,517,125 | 0.0% | 5.49% | -4.7% | |
| DICE THERAPEUTICS INC | $23,464,350 | -8.2% | 819,000 | 0.0% | 4.58% | +6.4% | ||
| KALV | KALVISTA PHARMACEUTICALS INC | $22,925,003 | +16.3% | 2,916,667 | 0.0% | 4.48% | +34.7% | |
| MRUS | MERUS N V | $22,562,338 | +18.9% | 1,226,214 | 0.0% | 4.40% | +37.8% | |
| CELC | CELCUITY INC | $21,580,207 | -26.8% | 2,105,386 | 0.0% | 4.21% | -15.2% | |
| AVTE | Buy | AEROVATE THERAPEUTICS INC | $16,820,308 | -23.2% | 833,927 | +11.5% | 3.28% | -11.0% |
| CABA | Buy | CABALETTA BIO INC | $16,318,786 | -6.9% | 1,973,251 | +4.1% | 3.19% | +7.9% |
| VECT | VECTIVBIO HLDG AG | $15,879,660 | -1.8% | 1,866,000 | 0.0% | 3.10% | +13.8% | |
| ANNX | ANNEXON INC | $12,397,193 | -25.5% | 3,220,050 | 0.0% | 2.42% | -13.7% | |
| SVRA | SAVARA INC | $12,385,485 | +25.8% | 6,351,531 | 0.0% | 2.42% | +45.8% | |
| MIST | MILESTONE PHARMACEUTICALS IN | $8,702,719 | -0.5% | 2,208,812 | 0.0% | 1.70% | +15.3% | |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $8,419,700 | -88.3% | 1,040,754 | -77.2% | 1.64% | -86.4% |
| New | THESEUS PHARMACEUTICALS INC | $6,837,600 | – | 770,000 | +100.0% | 1.34% | – | |
| TRVI | TREVI THERAPEUTICS INC | $5,642,541 | -4.1% | 3,050,022 | 0.0% | 1.10% | +11.1% | |
| FULC | Buy | FULCRUM THERAPEUTICS INC | $3,725,218 | +14.4% | 1,307,094 | +192.2% | 0.73% | +32.4% |
| LYRA | LYRA THERAPEUTICS INC | $1,857,582 | -36.0% | 924,170 | 0.0% | 0.36% | -25.8% | |
| New | AVALO THERAPEUTICS INC | $1,750,000 | – | 1,000,000 | +100.0% | 0.34% | – | |
| RALLYBIO CORP | $1,533,318 | -13.1% | 268,532 | 0.0% | 0.30% | +0.7% | ||
| AFMD | AFFIMED N V | $1,065,143 | -39.9% | 1,428,571 | 0.0% | 0.21% | -30.2% | |
| LIFE | Exit | ATYR PHARMA INC | $0 | – | -1,171,436 | -100.0% | -0.43% | – |
| INZY | Exit | INOZYME PHARMA INC | $0 | – | -2,709,987 | -100.0% | -0.48% | – |
| Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -1,770,705 | -100.0% | -1.19% | – | |
| Exit | LIANBIOsponsored ads | $0 | – | -4,793,047 | -100.0% | -1.32% | – | |
| PRVB | Exit | PROVENTION BIO INC | $0 | – | -1,118,653 | -100.0% | -1.99% | – |
| NVAX | Exit | NOVAVAX INC | $0 | – | -1,879,894 | -100.0% | -3.26% | – |
| AXSM | Exit | AXSOME THERAPEUTICS INC | $0 | – | -670,718 | -100.0% | -8.72% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.